id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-336177-p7b7yw28	Selvi, Valeria	Convalescent Plasma: A Challenging Tool to Treat COVID-19 Patients—A Lesson from the Past and New Perspectives	2020-09-22		.txt	text/plain	5464	221	40	WHO Pandemia WHO Director-General's opening remarks at the media briefing on COVID-19 -11 Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save livescurrent situation and perspectives Convalescent plasma as a potential therapy for COVID-19 Blood transfusion during the COVID-19 outbreak A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19 Treatment of COVID-19: old tricks for new challenges The convalescent sera option for containing COVID-19 Passive immunity in prevention and treatment of infectious diseases Convalescent plasma: new evidence for an old therapeutic tool? Points to consider in the preparation and transfusion of COVID-19 convalescent plasma Ebola virus convalescent blood products: where we are now and where we may need to go Evaluation of convalescent whole blood for treating Ebola virus disease in Convalescent plasma in Covid-19: possible mechanisms of action An augmented passive immune therapy to treat fulminant bacterial infections Position paper on use of convalescent plasma, serum or immune globulin concentrates as an element in response to an emerging virus Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome Use of convalescent plasma therapy in SARS patients in Hong Kong Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection Hyperimmune IV immunoglobulin Treatment The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience Risks and side effects of therapy with plasma and plasma fractions Treatment for emerging viruses: convalescent plasma and COVID-19 Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients Recommendations for investigational COVID-19 convalescent plasma-Food and Drug Administration Convalescent plasma is a clutch at straws in COVID-19 management! However, convalescent plasma was demonstrated to be associated with antiviral activity in patients with COVID-19 (convalescent plasma treatment was associated with higher rates of negative SARS-CoV-2 viral PCR results from nasopharyngeal swabs at 24, 48, and 72 hours); a statistically significant improvement was noted for the convalescent plasma treatment group compared to controls in the subgroup of patients without life-threatening COVID-19 (91% improvement in the plasma group compared to 68% in the control arm).	cache/cord-336177-p7b7yw28.txt	txt/cord-336177-p7b7yw28.txt
